The radiopharmaceutical sector is undergoing a transformation. What was once a niche discipline confined to academic cyclotron facilities and hospital radiopharmacies is now a multi-billion-dollar commercial manufacturing enterprise. The global nuclear medicine market reached $9.03 billion in 2024 and is projected to exceed $21 billion by 2030, driven largely by theranostic agents like 177Lu-PSMA-617 (Pluvicto) and 177Lu-DOTATATE (Lutathera) [1]. Novartis alone has invested in what it calls its "largest and most advanced radioligand therapy manufacturing facility" in Indianapolis, receiving FDA approval for commercial Pluvicto production in January 2024 [2].
This scale-up brings a familiar pharmaceutical challenge into unfamiliar territory: how do you perform rigorous visual inspection on products that are radioactive, time-critical, and physically inaccessible behind centimeters of shielding?
Why Visual Inspection Carries Outsized Importance in Radiopharmaceuticals
For most injectable pharmaceuticals, visual inspection is one layer in a multi-tiered particulate control strategy. Subvisible particle counts per USP <788>, container closure integrity testing, and environmental monitoring all contribute to the overall quality picture. Radiopharmaceuticals, however, operate under a critical exemption: USP <788> explicitly exempts radiopharmaceutical preparations from subvisible particulate matter testing requirements [3]. This means that for many radiopharmaceutical products, visual inspection is not merely one quality gate among several — it is the only direct assessment of particulate contamination performed before the product reaches the patient.
The significance of this exemption cannot be overstated. When a conventional injectable fails a subvisible particle count, the visual inspection program serves as a complementary detection method. When a radiopharmaceutical contains particulate matter, visual inspection is frequently the sole opportunity to identify the defect before administration. The IAEA's educational guidance on cyclotron-produced radiopharmaceuticals states the acceptance criterion plainly: "The product should be clear, colorless and free from particulate matter. The test should be completed on every batch prior to release of product" [4].
The Regulatory Landscape: Converging Expectations
The regulatory framework governing radiopharmaceutical visual inspection draws from multiple overlapping authorities, each with distinct but increasingly aligned expectations.
| Regulatory Standard | Scope | Visual Inspection Requirement |
|---|---|---|
| FDA 21 CFR 212 | PET drugs (United States) | Required as part of batch release quality control |
| FDA 21 CFR 211 | Non-PET radiopharmaceuticals (US) | 100% inspection per §211.167 |
| EU GMP Annex 1 (2022) | All sterile medicinal products | 100% container inspection, sections 8.30–8.32 |
| EU GMP Annex 3 (2008; revision pending) | Radiopharmaceuticals specifically | Defers to Annex 1; revision underway |
| USP <825> | Preparation, compounding, dispensing | Visual inspection before dispensing |
| USP <790> | Visible particulates in injections | Applies — provides reference method |
| IAEA Guidance | Cyclotron-produced radiopharmaceuticals | Clear, colorless, free from particulates |
| PIC/S Annex 3 (revision 2025–2026) | Radiopharmaceuticals (EU/PIC/S) | Under revision to align with Annex 1 |
The most consequential development is the December 2025 PIC/S concept paper proposing the first revision of Annex 3 since 2008. The joint EMA–PIC/S drafting group explicitly aims to "provide guidance within some areas that were not covered in the current version, clarify some sections, and support innovative pharmaceutical manufacturing and control approaches" [5]. This revision will need to reconcile the 100% inspection mandate of Annex 1 (2022) with the practical realities of handling radioactive materials — a tension that has persisted unresolved for years.
Meanwhile, the revised EU GMP Annex 1 (effective August 2023) states unambiguously: "Each filled container should be inspected for extraneous contamination or other defects. When inspection is done visually, it should be done under suitable and controlled conditions of illumination and background" [6]. The BioPhorum visual inspection team has noted that certain provisions in section 8.32 "could lead to confusion and even negatively impact product quality" when applied without consideration of product-specific constraints [7].
The Fundamental Tension: Time, Dose, and Visibility
Radiopharmaceutical visual inspection exists at the intersection of three competing pressures that do not apply to conventional parenterals:
Radiation Dose and ALARA
The ALARA principle (As Low As Reasonably Achievable) governs all radiation work. Every second an operator spends handling a radioactive vial contributes to their cumulative dose. This creates a direct conflict with thorough visual inspection, which benefits from extended observation time, multiple viewing angles, and repeated assessments. The IAEA acknowledges this tension by recommending that "for sake of radiation protection, the vial content is viewed through a leaded glass" rather than direct handling [4].
Half-Life Constraints and Release Timing
The physical half-lives of common radiopharmaceuticals impose absolute time boundaries on the entire quality control process:
| Radioisotope | Half-Life | Primary Application | Practical QC Window |
|---|---|---|---|
| 68Ga | 68 minutes | PET imaging (PSMA, DOTATATE) | ~30 minutes |
| 18F (FDG) | 109.7 minutes | PET imaging (oncology, neurology) | ~45–60 minutes |
| 99mTc | 6.0 hours | SPECT imaging (most common) | ~2–3 hours |
| 177Lu | 6.7 days | Therapy (Pluvicto, Lutathera) | ~24–48 hours |
| 131I | 8.0 days | Therapy (thyroid) | ~24–48 hours |
For 68Ga-labeled compounds, the entire synthesis, quality control battery, and release must occur within approximately one hour [8]. Standard sterility testing per USP <71> requires a 14-day incubation period — meaning that every short-lived radiopharmaceutical is released and administered to patients before sterility results are available [9]. This reality elevates visual inspection from a confirmatory check to a critical real-time quality gate. It is one of the few assessments that can actually be completed within the release window.
Physical Barriers to Observation
The shielding required to protect operators from gamma radiation simultaneously obstructs the very observation that inspection demands. Traditional approaches employ tungsten or lead "pigs" (transport containers) that completely obscure the vial contents, or leaded glass viewing windows that introduce color distortion. The IAEA explicitly warns that leaded glass can create "false observation of colour in the solution," recommending "non-tinted glass or indirect viewing using a mirror or video camera" as preferred alternatives [4].
This creates what might be called the radiopharmaceutical inspection paradox: the product is simultaneously more dependent on visual inspection (due to the USP <788> exemption) and more difficult to inspect visually (due to radiation shielding, time constraints, and physical inaccessibility).
How Inspection Is Actually Performed Today
In practice, radiopharmaceutical visual inspection falls into three broad categories depending on the facility type and production scale.
Hospital Radiopharmacies and Small-Scale Compounding
At the hospital level, visual inspection is typically performed by a trained nuclear medicine technologist or radiopharmacist who views the vial through a lead glass vial shield. These shields — available from suppliers like Nuclear-Shields and Gammadata — provide 360° transparency through high-density lead glass while attenuating radiation [10]. Some incorporate illumination systems to address the reduced light transmission inherent in leaded glass. The operator holds the shielded vial against white and black backgrounds, assessing clarity, color, and the absence of visible particulates. The entire process is constrained to seconds rather than the minutes typical of conventional parenteral inspection.
Cyclotron Facilities and PET Manufacturing
PET drug manufacturing under 21 CFR 212 occurs primarily within hot cells — heavily shielded enclosures with leaded glass viewing windows and remote manipulators. Visual inspection is performed either through the hot cell window (introducing optical distortion from thick leaded glass) or via camera systems mounted inside the cell. A 2023 FDA workshop on PET drugs revealed that 70% of PET manufacturers indicated FDA inspectors only "sometimes understand" the differences between traditional cGMP and PET-specific requirements, suggesting ongoing regulatory uncertainty around acceptable inspection practices [11].
Commercial Therapeutic Manufacturing
The newest and fastest-growing segment — commercial radioligand therapy production (Pluvicto, Lutathera) — faces the most complex inspection challenge. These facilities operate at pharmaceutical manufacturing scale under full GMP, producing therapeutic doses of 177Lu-labeled compounds that require the same level of visual inspection rigor as any other sterile injectable. The 6.7-day half-life of 177Lu provides more time than PET tracers, but the high-activity doses (typically 7.4 GBq / 200 mCi) demand robust shielding and remote handling throughout the process.
Automated Visual Inspection: The Industry Response
The convergence of regulatory pressure (Annex 1's 100% inspection mandate), market growth (commercial-scale production), and radiation safety requirements has driven significant investment in automated visual inspection systems purpose-built for radiopharmaceuticals.
Comecer: Robotic QC Hot Cells
Comecer (Italy) has developed a fully automated quality control and visual inspection hot cell equipped with a high-precision robotic arm. The system integrates container closure integrity testing, vial calibration, visual inspection, and labeling into a single shielded unit. The visual inspection station employs high-definition cameras with adjustable white and black backgrounds and high-speed vial rotation (up to 2,000 rpm), replicating the manual inspection protocol without operator radiation exposure [12].
Tema Sinergie: The VI System
Tema Sinergie's VI system (introduced 2022) is an automatic visual inspection and vial labeling machine designed specifically for nuclear medicine. The indoor unit — positioned inside the hot cell — features a high-resolution shielded camera, LED lighting in multiple positions, interchangeable white/black backgrounds, and a housing system that rotates the vial at high speed. The outdoor unit provides a high-resolution monitor for operator review. A complete visual inspection cycle takes less than 60 seconds, and all components are compatible with VPHP (Vaporized Hydrogen Peroxide) decontamination cycles [13].
Von Gahlen: Integrated Production Lines
Von Gahlen (Netherlands) takes a systems-integration approach, incorporating visual inspection as one component within fully integrated hot cell production lines. Their collaboration with ROTOP Pharmaka GmbH (announced September 2025) explicitly aims to bring "automated visual inspection (AVI) to the world of radiopharmaceutical manufacturing" [14]. Von Gahlen's systems integrate HPV contamination control, automatic glove testing, dispensing, and visual inspection into a single GMP Annex 1-compliant production line [15].
Transparent Radiation Shielding
An alternative approach to the shielding-versus-visibility problem comes from Radium Inc., whose patented ClearView transparent radiation shielding technology uses a liquid-based formulation that attenuates gamma radiation while remaining optically clear. Unlike leaded glass (which introduces yellow-brown color distortion) or tungsten pigs (which completely obscure the vial), ClearView shields allow unobstructed visual monitoring. The technology is already deployed at Memorial Sloan Kettering Cancer Center and the University of Michigan Health System, and is USP <825> compliant for radiopharmaceutical preparation and dispensing [16].
Unresolved Challenges and the Path Forward
Despite these technological advances, several fundamental questions remain unresolved for the radiopharmaceutical visual inspection community:
Inspector qualification and the baseline problem: For conventional injectables, Knapp-type qualification studies compare automated or semi-automated system performance against a human manual inspection baseline — operators physically holding, inverting, and rotating vials under controlled lighting. This standard baseline methodology fundamentally does not apply to radiopharmaceuticals. The handling restrictions imposed by radiation safety are not a temporary qualification inconvenience; they are a permanent production reality. The product will never be inspected via traditional manual handling, so establishing a manual inspection baseline is neither possible nor relevant. This means the qualified inspection method — whatever approach the facility selects (camera-based systems, inspection through lead glass shields, semi-automated systems, or fully automated AVI) — must serve as its own baseline. Qualification studies must demonstrate that the chosen method achieves acceptable probability of detection for the defined defect types and sizes, without requiring equivalence to a manual inspection standard that was never applicable to the product in the first place. The radiation dose accumulated during repeated qualification testing must itself comply with ALARA, adding further pressure to design efficient qualification protocols that minimize the number of radioactive presentations required.
Acceptance criteria for color: The IAEA notes that "a slight yellow color in the preparation is acceptable according to IP and Ph. Eur. specifications due to the fact that the sample is often viewed through tinted glass," but adds that "experience shows that FDG preparations are generally colorless" and that yellow coloration "indicates the likely presence of impurities arising during manufacturing" [4]. This ambiguity — is slight color acceptable or a warning sign? — is compounded when viewing through leaded glass that itself introduces color artifacts.
Post-decay inspection: The IAEA recommends that "a closer visual inspection may be performed on the reserve sample several half-lives post-production" [4]. This practice allows thorough inspection without radiation exposure concerns, but it occurs after the product has already been administered. It serves as a retrospective quality indicator rather than a release criterion — useful for trend analysis and process validation, but not for patient protection on the batch in question.
Regulatory harmonization: The pending revision of EU GMP Annex 3 (first update since 2008) will need to address how the 100% inspection requirement of Annex 1 applies to radiopharmaceuticals manufactured in hot cells. The concept paper acknowledges the need to "support innovative pharmaceutical manufacturing and control approaches" [5], but the specific provisions for visual inspection — including whether camera-based systems satisfy the requirement, what constitutes adequate inspector qualification, and how ALARA considerations factor into inspection program design — remain to be defined.
Implications for Inspection Program Design
Organizations manufacturing or compounding radiopharmaceuticals face a practical question: how to build a visual inspection program that satisfies regulatory expectations while respecting radiation safety constraints and production timelines. Several principles emerge from the current landscape:
Risk-based approach to inspection intensity. Not all radiopharmaceuticals carry the same inspection risk profile. Therapeutic doses (177Lu, 131I) with longer half-lives allow more thorough inspection protocols than diagnostic tracers (68Ga, 18F) where the QC window is measured in minutes. Inspection programs should be calibrated to the specific product's half-life, dose volume, patient population, and route of administration.
Camera-based systems as the emerging standard. The trend toward automated or semi-automated camera-based inspection inside hot cells addresses both the ALARA concern and the Annex 1 documentation requirement simultaneously. High-definition video records provide objective evidence of inspection that manual observation through leaded glass cannot match.
Surrogate-based qualification — but not a manual baseline. Inspector qualification and equipment validation require challenge sets with known defects. For radiopharmaceutical applications, these challenge sets must replicate the optical properties of the actual product (refractive index, color, viscosity) without containing radioactive material, allowing repeated testing without dose accumulation. However, it is critical to understand the role surrogates play in this context: they eliminate the radioactivity variable so that the chosen inspection method can be challenged repeatedly, but they do not exist to establish a traditional manual inspection baseline. The surrogate test sets should be evaluated using the same inspection method that will be used in production — not by having operators manually handle them as if they were conventional injectables. The goal is to qualify the actual production inspection process, not to demonstrate what a hypothetical manual inspection could achieve on a product that will never be manually inspected.
Process validation through reserve samples. Post-decay inspection of retained samples provides a mechanism to validate that the rapid, real-time inspection performed during release is detecting defects at an acceptable rate. This retrospective data supports ongoing process verification without adding time pressure to the release workflow.
References
- MarketsandMarkets. "Nuclear Medicine Market Size, Growth, Share & Trends Analysis." 2024. Available at: marketsandmarkets.com
- Novartis. "Novartis expands production of Pluvicto with addition of its largest and most advanced radioligand therapy manufacturing facility." Press release, January 5, 2024.
- United States Pharmacopeia. General Chapter <788> Particulate Matter in Injections. Note: "Radiopharmaceutical preparations are exempt from the requirements of this chapter."
- Schlyer, D. "Visual Inspection." IAEA Educational Materials: Radioisotope and Radiopharmaceutical Production using a Medical Cyclotron. International Atomic Energy Agency.
- PIC/S. "Concept Paper on the Revision of EU-PIC/S GMP Annex 3 (Radiopharmaceuticals)." Geneva, 16 December 2025.
- European Commission. EU GMP Annex 1: Manufacture of Sterile Medicinal Products. Revised 2022, effective August 2023. Sections 8.30–8.32.
- BioPhorum. "A view on the revised Annex 1: requirements on visual inspection processes." Published in The PDA Letter, March 2024.
- Journal of Nuclear Medicine. "Third Theranostics World Congress on Gallium-68 and PRRT." J Nucl Med. 2015;56(Suppl 2):2A. Total synthesis time including QC: ~1 hour for Ga-68 peptides.
- Yu, S. "Review of 18F-FDG synthesis and quality control." Biomedical Imaging and Intervention Journal. 2006;2(4):e57. doi:10.2349/biij.2.4.e57
- Nuclear-Shields. "Lead Glass Vial Shields." nuclear-shields.com. 360° transparency from high-density lead glass.
- Bunning, S. et al. "Proceedings: PET Drugs—A 2023 Workshop on Product Quality, Regulation, and Compliance." PMC, 2025. PMC12410302.
- Comecer. "Quality Control & Visual Inspection Solutions for Radiopharmacy Production." comecer.com, 2025.
- Tema Sinergie. "Tema Sinergie presents VI, the new automatic visual inspection and vial labelling system for nuclear medicine." temasinergie.com, September 2022.
- ROTOP Pharmaka GmbH / Von Gahlen. LinkedIn announcement, September 2025: collaboration to bring automated visual inspection to radiopharmaceutical manufacturing.
- Von Gahlen. "Fully Integrated Hot Cell Production Lines." vongahlen.com, September 2025.
- Radium Inc. "ClearView Transparent Radiation Shielding — Theranostics and Nuclear Medicine." radiuminc.com. Patent #10262763.
